Danish biotech firm Bavarian Nordic has received orders from the US agency BARDA, which exercised options worth 97 million dollars for the production and supply of a freeze-dried formulation of its smallpox vaccine, Jynneos. This was disclosed in a press release.
The order covers both the manufacturing of vaccine components and the delivery of doses, scheduled for production and supply during 2027. Invoicing for the bulk of the contract value will take place in 2026.
In connection with the deal, the company is raising its full-year 2026 guidance. Revenue is now expected to reach approximately DKK 5.5–5.7 billion, up from the previous estimate of DKK 5.0–5.2 billion. Revenue within the Public Preparedness business segment has been revised upward to DKK 2.3–2.5 billion (from 1.8-2.0). Meanwhile, the projected EBITDA margin has been raised to approximately 28 percent, up from the previous 25 percent.
Bavarian CEO Paul Chaplin described the order as a significant milestone in the company's partnership with the United States.
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97,2%) and services (2,8%).
Net sales are distributed geographically as follows: the United States (43.2%), Germany (18.6%), France (11.6%), Canada (3.6%), THE United Kingdom (3.4%), Finland (2.9%), Singapore (2.2%), Switzerland (1.7%), Australia (1.3%), Saudi Arabia (1.2%), Spain (0.6%), and others (9.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
